TY - JOUR AU - Ando, M. AU - Yanagisawa, N. PY - 2015 DA - 2015// TI - Epidemiology, clinical characteristics, and management of chronic kidney disease in human immunodeficiency virus-infected patients JO - World J Nephrol VL - 4 UR - https://doi.org/10.5527/wjn.v4.i3.388 DO - 10.5527/wjn.v4.i3.388 ID - Ando2015 ER - TY - JOUR AU - Nadkarni, G. N. AU - Konstantinidis, I. AU - Wyatt, C. M. PY - 2014 DA - 2014// TI - HIV and the aging kidney JO - Curr Opin HIV AIDS VL - 9 UR - https://doi.org/10.1097/COH.0000000000000067 DO - 10.1097/COH.0000000000000067 ID - Nadkarni2014 ER - TY - JOUR AU - Urata, M. AU - Narita, Y. AU - Fukunaga, M. PY - 2018 DA - 2018// TI - Simple formula for predicting drug removal rates during hemodialysis JO - Ther Apher Dial VL - 22 UR - https://doi.org/10.1111/1744-9987.12675 DO - 10.1111/1744-9987.12675 ID - Urata2018 ER - TY - JOUR AU - Hirata, S. AU - Izumi, S. AU - Furukubo, T. PY - 2004 DA - 2004// TI - Factors influencing the removal rate of drugs by hemodialysis JO - J Jpn Soc Dial Ther VL - 37 UR - https://doi.org/10.4009/jsdt.37.1893 DO - 10.4009/jsdt.37.1893 ID - Hirata2004 ER - TY - JOUR AU - Molto, J. AU - Graterol, F. AU - Miranda, C. PY - 2016 DA - 2016// TI - Removal of dolutegravir by hemodialysis in HIV-infected patients with end-stage renal disease JO - Antimicrob Agents Chemother VL - 60 UR - https://doi.org/10.1128/AAC.03131-15 DO - 10.1128/AAC.03131-15 ID - Molto2016 ER - TY - JOUR AU - Ware, D. AU - Palella, F. J. AU - Chew, K. W. PY - 2018 DA - 2018// TI - Prevalence and trends of polypharmacy among HIV-positive and negative men in the multicenter AIDS cohort study from 2004 to 2016 JO - PLoS One VL - 13 UR - https://doi.org/10.1371/journal.pone.0203890 DO - 10.1371/journal.pone.0203890 ID - Ware2018 ER - TY - JOUR AU - Núñez-Núñez, M. AU - Castañeda-Macías, I. AU - Sandoval-Fernández Del Castillo, S. PY - 2018 DA - 2018// TI - Potential interactions in a cohort of elderly hiv-positive patients JO - Farm Hosp VL - 42 ID - Núñez-Núñez2018 ER - TY - STD TI - Ambrisentan (Letairis) prescribing information. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022081s033lbl.pdf. UR - https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022081s033lbl.pdf ID - ref8 ER - TY - JOUR AU - Sise, M. E. AU - Courtwright, A. M. AU - Channick, R. N. PY - 2013 DA - 2013// TI - Pulmonary hypertension in patients with chronic and end-stage kidney disease JO - Kidney Int VL - 84 UR - https://doi.org/10.1038/ki.2013.186 DO - 10.1038/ki.2013.186 ID - Sise2013 ER - TY - JOUR AU - Enderle, Y. AU - Witt, L. AU - Wilkens, H. PY - 2017 DA - 2017// TI - Simultaneous quantification of endothelin receptors antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary artery hypertension JO - J Pharm Biomed Anal VL - 143 UR - https://doi.org/10.1016/j.jpba.2017.05.052 DO - 10.1016/j.jpba.2017.05.052 ID - Enderle2017 ER - TY - JOUR AU - Dingemanse, J. AU - Giersbergen, P. L. AU - Patat, A. AU - Nilsson, P. N. PY - 2010 DA - 2010// TI - Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants JO - Antivir Ther VL - 15 UR - https://doi.org/10.3851/IMP1506 DO - 10.3851/IMP1506 ID - Dingemanse2010 ER - TY - STD TI - Bosentan Tracleer prescribing information. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209279s000lbl.pdf. UR - https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209279s000lbl.pdf ID - ref12 ER - TY - JOUR AU - Moltó, J. AU - Curran, A. AU - Miranda, C. PY - 2018 DA - 2018// TI - Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients JO - J Antimicrob Chemother VL - 73 UR - https://doi.org/10.1093/jac/dkx459 DO - 10.1093/jac/dkx459 ID - Moltó2018 ER - TY - JOUR AU - Markert, C. AU - Hellwig, R. AU - Burhenne, J. PY - 2013 DA - 2013// TI - Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1 JO - Eur J Clin Pharmacol VL - 69 UR - https://doi.org/10.1007/s00228-013-1529-1 DO - 10.1007/s00228-013-1529-1 ID - Markert2013 ER - TY - JOUR AU - Markert, C. AU - Kastner, I. M. AU - Hellwig, R. PY - 2015 DA - 2015// TI - The effect of induction of CYP3A4 by St John’s wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype JO - Basic Clin Pharmacol Toxicol VL - 116 UR - https://doi.org/10.1111/bcpt.12332 DO - 10.1111/bcpt.12332 ID - Markert2015 ER -